'Slow Money As Bad As No Money' – SMEs Struggle For Superbug Funds
The key to getting funding for small biotechs which focus on tackling antimicrobial resistance is to get private investors interested to top up 'push' incentives from the likes of CARB-X, the AMR Centre's Peter Jackson tells Scrip.
You may also be interested in...
As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.
Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.
Ex-Pharmacyclics CEO Bob Duggan is to invest $25m into Summit Therapeutics, taking a near 49% stake in the UK firm and helping it fund Phase III trials for the Oxford-based firm's lead antibiotic candidate ridinilazole.